March 31, 1997
VIA EDGAR
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: Cryomedical Sciences, Inc. - Form 12b-25
Dear Sir or Madam:
On behalf of our client, Cryomedical Sciences, Inc.
(the "Company"), attached for filing please find a Form
12b-25 relating to the Company's Transition Report on
Form 10-K for the period ended December 29, 1996.
Sincerely yours,
/s/ Leonard J. Breslow
Leonard J. Breslow
LJB/ac
Enclosures
cc: National Association of Securities Dealers, Inc.
(w/Enc. - by UPS)
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Commission File Number 0-18170
NOTIFICATION OF LATE FILING
(Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [
] Form 10-Q [ ] Form N-SAR
For Period Ended:
[X] Transition Report on Form 10-K [ ] Transition
Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition
Report on Form N-SAR
[ ] Transition Report on Form 11-K
For Transition Period Ended: December 29, 1996
Read attached instruction sheet before preparing form. Please
print or type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Cryomedical Sciences, Inc.
Full name of registrant
Former name if applicable
1300 Piccard Drive
Address of principal executive office (Street and number)
Rockville, Maryland 20850
City, State and Zip Code
PART II - RULES 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check
appropriate box.)
(a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without
unreasonable effort or expense;
(b) The subject annual report, semi-annual report,
transition report on Form 10-K, Form 20-F, 11-K or Form -
[X] N-SAR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q,
or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c) The account's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-
K, 20-F, 11-K, 10-Q, N-SAR or the transition report portion
thereof could not be filed within the prescribed time period.
(Attach extra sheets if needed.)
The Registrant is unable to timely file its Form
10-K primarily due to the delays associated with
changing the Registrant's fiscal year. The Registrant
fully intends to file the transition report on Form 10-K
on or before April 13, 1997.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in
regard to this notification
Richard Fisher
(301) 417-7070
(Name) (Area
code) (Telephone number)
(2) Have all other periodic reports required under Section
13 or 15(d) of the Securities exchange Act of 1934 or Section 30
of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required
to file such report(s) been filed? If the answer is no, identify
report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the
subject report or portion thereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
Cryomedical
Sciences, Inc.
(Name of registrant as specified in charter)
has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date 3/28/97 By/s/ Richard Reinhart
Dr. Richard Reinhart, Ph.D.,
President and Chief Executive Officer
Instruction. The form may be signed by an
executive officer of the registrant or by any other duly
authorized representative. The name and title of the
person signing the form shall be typed or printed
beneath the signature. If the statement is signed on
behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the
representative's authority to sign on behalf of the
registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).
